MRK Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Merck & Co Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 127.75 USD -0.4%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast MRK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRK is 143.84 USD with a low forecast of 119.18 USD and a high forecast of 162.75 USD.

MRK Lowest Forecast

Wall Street Target

MRK Average Forecast

Wall Street Target

MRK Highest Forecast

Wall Street Target

7% Downside

13% Upside

27% Upside

The latest public price target was made on Mar 27, 2024 by Unknown Analyst from Truist Financial , who expects MRK stock to rise by 11% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Unknown Analyst Truist Financial	142 USD Upside 11%	1 month ago Mar 27, 2024	Merck (MRK) PT Raised to $142 at Truist Securities StreetInsider
Mohit Bansal Wells Fargo	135 USD Upside 6%	1 month ago Mar 27, 2024	Merck (MRK) PT Raised to $135 at Wells Fargo StreetInsider
Akash Tewari Jefferies	145 USD Upside 14%	1 month ago Mar 27, 2024	Merck (MRK) PT Raised to $145 at Jefferies, 'modeling a strong launch out of the gate' for Winrevair StreetInsider
Evan David Seigerman Loop Capital Markets	132 USD Upside 3%	5 months ago Nov 22, 2023	Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team" Benzinga
Jay Olson Oppenheimer	294 USD Upside 130%	1 year ago Apr 12, 2023	These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts Benzinga
Unknown Analyst Morgan Stanley	99 USD Downside 23%	1 year ago Feb 3, 2023	Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $99 Benzinga
Unknown Analyst Wells Fargo	120 USD Downside 6%	1 year ago Feb 3, 2023	Wells Fargo Maintains Overweight on Merck & Co, Lowers Price Target to $120 Benzinga

Show More Price Targets

Show Less Price Targets

Price Target	142 USD
Upside/Downside	11%

Price Target	135 USD
Upside/Downside	6%

Price Target	145 USD
Upside/Downside	14%

Price Target	132 USD
Upside/Downside	3%

Price Target	294 USD
Upside/Downside	130%

Price Target	99 USD
Upside/Downside	23%

Price Target	120 USD
Upside/Downside	6%

Show More Price Targets

Show Less Price Targets

Verano Holdings Corp

149% Upside

Panion & BF Biotech Inc

13% Upside

RPG Life Sciences Limited

68% Downside

Sunflower Pharmaceutical Group Co Ltd

12% Downside

Verano Holdings Corp

149% Upside

Panion & BF Biotech Inc

13% Upside

RPG Life Sciences Limited

68% Downside

Sunflower Pharmaceutical Group Co Ltd

12% Downside

Kopran Ltd

70% Downside

Aurisco Pharmaceutical Co Ltd

30% Upside

Zhejiang Xianju Pharmaceutical Co Ltd

33% Upside

Ucb SA

7% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Merck & Co Inc's revenue is 5%. The projected CAGR for the next 3 years is 6%.

5%

6%

-1%

What are analyst estimates?

Operating Income
Forecast

For the last 8 years the compound annual growth rate for Merck & Co Inc's operating income is -9%. The projected CAGR for the next 3 years is 99%.

-9%

99%

-28%

What are analyst estimates?

Net Income
Forecast

For the last 8 years the compound annual growth rate for Merck & Co Inc's net income is -27%. The projected CAGR for the next 3 years is 323%.

-27%

323%

-51%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for MRK is 143.84 USD with a low forecast of 119.18 USD and a high forecast of 162.75 USD.

For the last 8 years the compound annual growth rate for Merck & Co Inc's revenue is 5%. The projected CAGR for the next 3 years is 6%.

For the last 8 years the compound annual growth rate for Merck & Co Inc's operating income is -9%. The projected CAGR for the next 3 years is 99%.

For the last 8 years the compound annual growth rate for Merck & Co Inc's net income is -27%. The projected CAGR for the next 3 years is 323%.

Join more than 133,800+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.